Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.

The pattern of loss of heterozygosity (LOH) on chromosome 17 in human breast cancer is complicated and shows many different regions of loss. In an attempt to narrow down the relevant regions of LOH on chromosome 17, we have studied the deletion pattern and its association with clinical parameters in 1280 breast carcinoma-venous blood lymphocyte pairs. In total, 42 different chromosome 17 loci were investigated, and between 25 and 625 cases were analyzed at each locus. The frequency of LOH observed on the p arm was much higher than that observed on the q arm. The opposite effect was observed in 52 ovarian cancer cases investigated, with less LOH on 17p than on 17q. Patterns of loss consistent with interstitial and terminal deletions, as well as loss of either the p or q arm or monosomy 17 were observed. To determine whether loss at particular loci may be associated with biological features of breast tumors, clinical data including age of onset, family history of breast cancer, tumor histopathology, tumor size, estrogen receptor (ER) status, and occurrence of lymph node or distant metastases were collected for each case. Overall, large-sized, ER-negative, lymph node-positive ductal tumors showed the highest frequencies of LOH, with ER-negative and ductal tumors showing LOH for markers along the majority of the chromosome. Eight regions of chromosome 17 appear to be associated with human breast cancer, two on 17p and six on 17q. These regions were not necessarily in the areas exhibiting the highest frequencies of LOH but were defined by interstitial and terminal deletions in multiple independent cases. Seven of these regions showed statistically significant differences in LOH associated with clinical parameters. These data strongly suggest that loci on chromosome 17 may determine aspects of tumor presentation and disease behavior in human breast cancer and pinpoint candidate tumor suppressor gene loci.

[1]  U. Hamann,et al.  Allelic imbalance in three distinct regions on chromosome 17q in sporadic breast cancer correlates with prognostic parameters , 1997 .

[2]  A. Feinstein,et al.  Clinical symptoms and comorbidity: significance for the prognostic classification of cancer , 1996, Cancer.

[3]  N. Phillips,et al.  Allelic deletion on chromosome 17p13.3 in early ovarian cancer. , 1996, Cancer research.

[4]  P. Basset,et al.  Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. , 1995, Genomics.

[5]  C. Herrington,et al.  Correlation of numerical chromosome 11 and 17 imbalance with metastasis of primary breast cancer to lymph nodes , 1995, The Journal of pathology.

[6]  S. Rogatto,et al.  Cytogenetic report of a male breast cancer. , 1995, Cancer genetics and cytogenetics.

[7]  A. Jeffreys,et al.  A somatic BRCA1 mutation in an ovarian tumour , 1995, Nature Genetics.

[8]  E. Mallon,et al.  Interphase cytogenetic analysis of erbB2 and topollα co‐amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ , 1995, International journal of cancer.

[9]  H. Scherthan,et al.  Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes. , 1995, Oncogene.

[10]  Ming K. Lee,et al.  22 genes from chromosome 17q21: cloning, sequencing, and characterization of mutations in breast cancer families and tumors. , 1995, Genomics.

[11]  S. Mazoyer,et al.  Five distinct deleted regions on chromosome 17 defining different subsets of human primary breast tumors. , 1995, Oncology.

[12]  F. Collins,et al.  Somatic mutations in the BRCA1 gene in sporadic ovarian tumours , 1995, Nature Genetics.

[13]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[14]  K. Buetow,et al.  A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. , 1994, American journal of human genetics.

[15]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[16]  M. J. van de Vijver,et al.  Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. , 1994, Cancer research.

[17]  Å. Borg,et al.  High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas. , 1994, Journal of the National Cancer Institute.

[18]  H. Nevanlinna,et al.  Evidence for involvement of BRCA1 in sporadic breast carcinomas. , 1994, Cancer research.

[19]  C. Croce,et al.  Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions. , 1994, Cancer research.

[20]  R. Zeillinger,et al.  Patterns of allele losses suggest the existence of five distinct regions of loh on chromosome 17 in breast cancer , 1994, International journal of cancer.

[21]  R. Lidereau,et al.  Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted. , 1993, Cancer research.

[22]  G. Casey,et al.  Functional evidence for a breast cancer growth suppressor gene on chromosome 17. , 1993, Human molecular genetics.

[23]  T. Katagiri,et al.  A novel metalloprotease/disintegrin–like gene at 17q21.3 is somatically rearranged in two primary breast cancers , 1993, Nature genetics.

[24]  G. Merlo,et al.  Genetic and molecular heterogeneity of breast cancer cells. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[25]  A. Thompson,et al.  Allelic loss on a chromosome 17 in ductal carcinoma in situ of the breast. , 1993, Cancer research.

[26]  M. Carcangiu,et al.  Allelic loss in ovarian cancer , 1993, International journal of cancer.

[27]  P. Devilee,et al.  Allele loss patterns on chromosome 17q in 109 breast carcinomas indicate at least two distinct target regions. , 1993, Oncogene.

[28]  J. Russo,et al.  The pathology of breast cancer: staging and prognostic indicators. , 1992, Journal of the American Medical Women's Association.

[29]  J. Barrett,et al.  Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. , 1992, Cancer research.

[30]  M. Skolnick,et al.  The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer. , 1992, Cancer research.

[31]  J. Nesland,et al.  Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas , 1992, Genes, chromosomes & cancer.

[32]  C. Benz,et al.  Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. , 1992, Cancer treatment and research.

[33]  A. Tanigami,et al.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. , 1990, Cancer research.

[34]  H. J. Evans,et al.  Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. , 1990, Oncogene.

[35]  C. M. Steel,et al.  Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis , 1990, The Lancet.

[36]  R. Hutter.  At last--worldwide agreement on the staging of cancer. , 1987, Archives of surgery.